346 related articles for article (PubMed ID: 27404978)
21. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
Kara Ö; Zarakolu P; Aşçioğlu S; Etgül S; Uz B; Büyükaşik Y; Akova M
Infect Dis (Lond); 2015; 47(10):686-93. PubMed ID: 26024284
[TBL] [Abstract][Full Text] [Related]
23. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan.
Asai N; Sakanashi D; Suematsu H; Kato H; Hagihara M; Nishiyama N; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2018 Jul; 24(7):505-509. PubMed ID: 29548627
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis.
Bogan C; Kaye KS; Chopra T; Hayakawa K; Pogue JM; Lephart PR; Bheemreddy S; Lazarovitch T; Zaidenstein R; Perez F; Bonomo RA; Marchaim D
Am J Infect Control; 2014 Jun; 42(6):612-20. PubMed ID: 24837111
[TBL] [Abstract][Full Text] [Related]
25. Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae.
Martirosov DM; Lodise TP
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):266-75. PubMed ID: 27033631
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009.
Zilberberg MD; Shorr AF
J Hosp Med; 2013 Oct; 8(10):559-63. PubMed ID: 24022878
[TBL] [Abstract][Full Text] [Related]
27. Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies.
Woerther PL; Micol JB; Angebault C; Pasquier F; Pilorge S; Bourhis JH; de Botton S; Gachot B; Chachaty E
J Med Microbiol; 2015 Jul; 64(7):676-681. PubMed ID: 25934549
[TBL] [Abstract][Full Text] [Related]
28. Impact of neutropenia on the clinical outcomes of Staphylococcus aureus bacteremia in patients with hematologic malignancies: a 10-year experience in a tertiary care hospital.
Ryu BH; Lee SC; Kim M; Eom Y; Jung J; Kim MJ; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):937-943. PubMed ID: 31925572
[TBL] [Abstract][Full Text] [Related]
29. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
30. High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases.
Liu LP; Lin QS; Yang WY; Chen XJ; Liu F; Chen X; Ren YY; Ruan M; Chen YM; Zhang L; Zou Y; Guo Y; Zhu XF
Antimicrob Resist Infect Control; 2023 Jul; 12(1):66. PubMed ID: 37422680
[TBL] [Abstract][Full Text] [Related]
31. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
[TBL] [Abstract][Full Text] [Related]
32. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy.
Johnson MP; Ramphal R
J Infect Dis; 1990 Oct; 162(4):981-3. PubMed ID: 2205658
[TBL] [Abstract][Full Text] [Related]
33. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
34. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
[TBL] [Abstract][Full Text] [Related]
35. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies.
Liss BJ; Vehreschild JJ; Cornely OA; Hallek M; Fätkenheuer G; Wisplinghoff H; Seifert H; Vehreschild MJ
Infection; 2012 Dec; 40(6):613-9. PubMed ID: 22665143
[TBL] [Abstract][Full Text] [Related]
36. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
37. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers.
Dickstein Y; Edelman R; Dror T; Hussein K; Bar-Lavie Y; Paul M
J Hosp Infect; 2016 Sep; 94(1):54-9. PubMed ID: 27392978
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
[TBL] [Abstract][Full Text] [Related]
39. Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.
Torres-González P; Ortiz-Brizuela E; Cervera-Hernandez ME; Bobadilla-Del Valle M; Martínez-Gamboa A; Sifuentes-Osornio J; Ponce-de-Leon A
Diagn Microbiol Infect Dis; 2016 Oct; 86(2):243-8. PubMed ID: 27519297
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.
Khoo AL; Zhao YJ; Teng M; Ying D; Jin J; Chee YL; Poon LM; Lim SE; Koh LP; Chng WJ; Lim BP; Hsu LY; Chai LYA
Int J Antimicrob Agents; 2018 Sep; 52(3):350-357. PubMed ID: 29751120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
